Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE

Key Points

• Jupiter Topco LLC acquired 1.07 million shares of Monte Rosa Therapeutics valued at approximately $25.96 million, giving it a 1.26% stake. Institutional investors collectively own nearly 80% of GLUE.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $28.50, despite several recent target reductions.
• Monte Rosa reported a quarterly loss of $0.43 per share and revenue of $8.97 million, missing analyst expectations for both measures. Shares opened at $13.38, while insiders sold about 79,603 shares worth $1.73 million over the past 90 days.

Jupiter Topco LLC acquired a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,072,494 shares of the company's stock, valued at approximately $25,965,000. Jupiter Topco LLC owned 1.26% of Monte Rosa Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in GLUE. ProShare Advisors LLC boosted its position in Monte Rosa Therapeutics by 11.8% during the fourth quarter. ProShare Advisors LLC now owns 11,374 shares of the company's stock worth $178,000 after purchasing an additional 1,199 shares during the period. Allworth Financial LP bought a new stake in shares of Monte Rosa Therapeutics in the second quarter valued at approximately $30,000. MetLife Investment Management LLC boosted its holdings in Monte Rosa Therapeutics by 7.5% in the 4th quarter. MetLife Investment Management LLC now owns 26,187 shares of the company's stock worth $411,000 after buying an additional 1,831 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Monte Rosa Therapeutics by 2.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 119,836 shares of the company's stock worth $540,000 after buying an additional 2,529 shares during the period. Finally, SG Americas Securities LLC grew its stake in Monte Rosa Therapeutics by 18.5% in the 1st quarter. SG Americas Securities LLC now owns 20,468 shares of the company's stock valued at $337,000 after buying an additional 3,189 shares in the last quarter. 79.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on GLUE. Jefferies Financial Group reaffirmed a "buy" rating on shares of Monte Rosa Therapeutics in a report on Monday, July 27th. Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Wedbush reduced their price objective on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an "outperform" rating for the company in a research note on Monday, August 3rd. Weiss Ratings lowered shares of Monte Rosa Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a report on Tuesday, August 11th. Finally, TD Cowen upgraded shares of Monte Rosa Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $28.50.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ:GLUE opened at $13.38 on Friday. The firm has a market capitalization of $1.14 billion, a PE ratio of -7.60 and a beta of 1.59. Monte Rosa Therapeutics, Inc. has a 52-week low of $4.60 and a 52-week high of $25.77. The firm has a fifty day moving average of $19.72 and a 200 day moving average of $18.63.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. The firm had revenue of $8.97 million for the quarter, compared to analysts' expectations of $12.91 million. On average, sell-side analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.32 EPS for the current fiscal year.

Insider Transactions at Monte Rosa Therapeutics

In related news, COO Jennifer Champoux sold 2,176 shares of the business's stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total value of $41,344.00. Following the completion of the sale, the chief operating officer owned 62,371 shares in the company, valued at $1,185,049. The trade was a 3.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Anthony M. Manning sold 10,000 shares of the company's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the sale, the director directly owned 10,000 shares of the company's stock, valued at approximately $231,100. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 79,603 shares of company stock valued at $1,725,081 over the last 90 days. Company insiders own 6.40% of the company's stock.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.

Want to see what other hedge funds are holding GLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source